Research Topics
Species | Paul GordonSummaryAffiliation: Columbia University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The natural history of primary lateral sclerosisP H Gordon
Department of Neurology, Columbia University, New York, NY, USA
Neurology 66:647-53. 2006....- Randomized controlled phase II trial of glatiramer acetate in ALSP H Gordon
Department of Neurology, Columbia University, NY, USA
Neurology 66:1117-9. 2006..01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy... - A screening assessment of cognitive impairment in patients with ALSPaul H Gordon
Departmen of Neurology, Columbia University, New York, USA
Amyotroph Lateral Scler 8:362-5. 2007..Behavioral and motor impairment is associated with depressive symptoms in caregivers. Studies with formal neuropsychological tests are needed to determine the sensitivity and specificity of the screen in ALS... 
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALSPaul H Gordon
Department of Neurology, Columbia University, New York, USA
Amyotroph Lateral Scler 9:212-22. 2008..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...- Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trialPaul H Gordon
Department of Neurology, Columbia University, New York, NY, USA
Lancet Neurol 6:1045-53. 2007..Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS)... - Outcome measures for early phase clinical trialsPaul H Gordon
Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
Amyotroph Lateral Scler 8:270-3. 2007..The ALSFRS-R most strongly predicted survival and provided the most complete data, but large changes may be necessary before patients perceive treatment effects... - Advances in clinical trials for amyotrophic lateral sclerosisPaul H Gordon
Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, 9th Floor, 710 West 168th Street, New York, NY 10032, USA
Curr Neurol Neurosci Rep 5:48-54. 2005..This article is devoted to the recent evolution of clinical trials in ALS and discusses specific trials conducted during the past 5 years... - Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALSP H Gordon
Department of Neurology, Columbia University, New York, NY, USA
Neurology 72:1948-52. 2009..To determine how clinical features at the first evaluation and in follow-up can be used to suggest a diagnostic outcome for patients with only upper motor neuron (UMN) signs at disease onset... - Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery LGregg W Stone
Columbia University Medical Center, Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
Circulation 119:680-6. 2009..The safety and efficacy of EES after 1 year have not been reported... - Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarctionGregg W Stone
Columbia University Medical Center and New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY 10022, USA
N Engl J Med 360:1946-59. 2009.... - Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trialRoxana Mehran
Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA
Lancet 374:1149-59. 2009..Here, we assess whether these initial benefits were maintained at 1 year of follow-up... - The ALSFRSr predicts survival time in an ALS clinic populationP Kaufmann
Department of Neurology, College of Physicians and Surgeons, The Neurologic Institute, Columbia University, 710 W 168th Street, New York, NY 10032, USA
Neurology 64:38-43. 2005..To determine whether the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRSr), a predictor of survival time in ALS clinical trials, predicts survival time in an ALS clinic population... 
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase IIIPetra Kaufmann
Department of Neurology, Clinical Coordinating Center, Columbia University, New York, NY 10032, USA
Ann Neurol 66:235-44. 2009..Our aims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in a Phase III clinical trial...- Prevalence of fatigue and depression in ALS patients and change over timeM C McElhiney
New York State Psychiatric Institute, Unit 51, New York, NY 10032, USA
J Neurol Neurosurg Psychiatry 80:1146-9. 2009..Amyotrophic lateral sclerosis (ALS) patients report both fatigue and depression. It is not clear how frequently each occurs, to what extent they occur together, how each relates to ALS disease status, or their stability over time... - Development and evaluation of a self-administered version of the ALSFRS-RJ Montes
Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032
Neurology 67:1294-6. 2006..The self-administered ALSFRS-R showed excellent reliability (intraclass correlation = 0.93, 95% CI: 088 to 0.96) and similar sensitivity to change over time vs the standard evaluator-administered ALSFRS-R... - Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosisP H Gordon
Department of Neurology, Columbia University, New York, USA
Neurology 62:1845-7. 2004..057), and blood urea nitrogen and liver enzymes became elevated (p < 0.05). Using these data, the authors have designed and launched a phase III trial... - Quantitative objective markers for upper and lower motor neuron dysfunction in ALSH Mitsumoto
Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
Neurology 68:1402-10. 2007..To investigate the value of objective biomarkers for upper (UMN) and lower (LMN) motor neuron involvement in ALS... - Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary ArteAdriano Caixeta
Columbia University Medical Center and the Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA
JACC Cardiovasc Interv 3:1220-8. 2010..The purpose of this study was to investigate long-term 3-year clinical outcomes of an everolimus-eluting stent (EES) versus a paclitaxel-eluting stent (PES)... - Identification of a novel D109Y mutation in Cu/Zn superoxide dismutase (sod1) gene associated with amyotrophic lateral sclerosisAli Naini
H Houston Merritt Center, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA
J Neurol Sci 254:17-21. 2007..This amino acid change in the protein however, did not alter the catalytic activity of the SOD1 enzyme as there was no change in the enzymatic activity of purified SOD1 from the patient's erythrocytes compared to control... - Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV TrialAmir Halkin
Cardiovascular Research Foundation, New York, NY 10022, USA
Am Heart J 150:1163-70. 2005..CONCLUSIONS: The polymer-based paclitaxel-eluting TAXUS stent safely reduces clinical and angiographic restenosis in patients with preserved as well as moderate impairment of baseline renal function... - Early electrodiagnostic findings in Guillain-Barré syndromeP H Gordon
Department of Neurology, University of New Mexico School of Medicine, 915 Camino de Salud NE, Albuquerque, NM 87131, USA
Arch Neurol 58:913-7. 2001..Although nerve conduction studies are a diagnostic aid, the characteristic electrical changes may not evolve for several weeks. Early diagnosis of GBS is important, however, because early treatment has been shown to improve outcome... - Web-based data management for a phase II clinical trial in ALSRichard Buchsbaum
Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
Amyotroph Lateral Scler 10:374-7. 2009..Given sufficient resources, a comprehensive web-based data management system can meet the need for clean, available data in clinical trials in ALS and similar diseases, and can contribute significantly to their efficient execution... - Neuroleptic malignant syndrome in advanced Parkinson's diseaseP H Gordon
Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York, USA
Mov Disord 16:960-2. 2001..His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa... - Amyotrophic lateral sclerosis with ragged-red fibersMichio Hirano
Department of Neurology, Columbia University Medical Center, 3 317 Russ Berrie Medical Science Pavilion, 1150 St Nicholas Ave, New York, NY 10032, USA
Arch Neurol 65:403-6. 2008..Motor neuron diseases (amyotrophic lateral sclerosis [ALS] and spinal muscular atrophy [SMA]) have been rarely associated with mitochondrial respiratory chain defects... - Oxidative stress biomarkers in sporadic ALSHiroshi Mitsumoto
Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University Medical Center, New York, NY 10032, USA
Amyotroph Lateral Scler 9:177-83. 2008..ELISA may be reliable and thus useful in epidemiology studies requiring large numbers of samples to determine the significance of increased oxidative stress markers in SALS. Further studies are required... - Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALSPaul H Gordon
Neurology 67:1314-5; author reply 1314-5. 2006 - The Timed Up and Go test: predicting falls in ALSJacqueline Montes
Department of Neurology, College of Physicians and Surgeons, The Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
Amyotroph Lateral Scler 8:292-5. 2007..The TUG test can guide management of patients with ALS; a time of 14 s can be used to prompt the recommendation for mobility aids to prevent falls... - Selecting promising ALS therapies in clinical trialsYing Kuen Cheung
Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY 10032, USA
Neurology 67:1748-51. 2006.... - Minocycline-induced skin and dental pigmentationsTahseen Mozaffar
Department of Neurology, University of California, Irvine, 101 The City Drive South, Bldg. 22 C, Route 13, Orange, CA 92868, USA
Neurology 67:2185. 2006 - Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trialPetra Kaufmann
Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, New York, NY, USA
Amyotroph Lateral Scler 8:42-6. 2007..97 (95% CI 0.93-0.98). We conclude that the ALSFRS-R shows excellent inter- and intra-rater reliability, and reliability of telephone administration when used as primary outcome measure in a multicenter ALS trial... - ALSFRS-RPaul H Gordon
Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, New York, NY 10032, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 5:90-3. 2004..Unlike the other standard outcome measures currently employed, the ALSFRS-R is also a measure of global function... - Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patientsR Lee Mosley
Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198 5800, USA
Amyotroph Lateral Scler 8:235-42. 2007..These data show significant humoral responses and cytokine trends following GA immunization in ALS patients... - Amyotrophic lateral sclerosisPaul H Gordon
Eleanor and Lou Gehrig Muscular Dystrophy Association Amyotrophic Lateral Sclerosis Research Center, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Sci Aging Knowledge Environ 2003:dn2. 2003..Cognition, the extraocular muscles, and the urinary sphincters were spared. Respiratory muscle weakness was a late manifestation... - An observational study of cognitive impairment in amyotrophic lateral sclerosisGregory A Rippon
Department of Neurology, Gertrude H. Sergievsky Center, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Eleanor and Lou Gehrig MDA/ALS Research Center, New York, NY, USA
Arch Neurol 63:345-52. 2006..CONCLUSIONS: Nearly a third of the patients with ALS showed evidence of cognitive impairment in a pattern consistent with frontotemporal lobar dementia. Cognitive performance was not related to site of onset or survival... - Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum?Michael J Strong
Department of Clinical Neurological Sciences, The University of Western Ontario, The Cell Biology Research Group, Roberts Research Institute, London, Ontario, Canada
Amyotroph Lateral Scler Other Motor Neuron Disord 6:8-16. 2005..Only through the development and application of exacting clinical diagnostic criteria to epidemiological studies, along with greater numbers of post-mortem examinations, however, will these questions be answered fully... - Woman with a 26-year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexesPaul H Gordon
Department of Neurology, Division of Movement Disorders, Columbia-Presbyterian Medical Center, New York, New York 10032, USA
Mov Disord 19:950-61. 2004..A woman who had her first serious fall at age 48 years subsequently developed neurological symptoms. Her case is described, differential diagnoses are presented, pathology is discussed, and a final diagnosis is reached... - Reaction time and movement time after embryonic cell implantation in Parkinson diseasePaul H Gordon
Department of Neurology and Clinical Motor Physiology Laboratory, Columbia-Presbyterian Medical Center, New York, NY 10032, USA
Arch Neurol 61:858-61. 2004..These findings support further research into nigral cell implantation for PD... - Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis miceRebecca Banerjee
Department of Pharmacology and Experimental Neuroscience, Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, Nebraska, United States of America
PLoS ONE 3:e2740. 2008..Thus, the role of T cell immunity in disease was investigated in human G93A superoxide dismutase 1 (SOD1) transgenic (Tg) mice and subsequently in ALS patients... - Lou Gehrig, rawhide, and 1938Melissa Lewis
Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Columbia University, New York, NY, USA
Neurology 68:615-8. 2007..A photograph of Gehrig from October 1939 showed hand atrophy. Photos from the spring of 1938 showed normal hand muscles and leg function, implying that visible signs first appeared after May 1938... 
Amyotrophic lateral sclerosis: an emerging era of collaborative gene discoveryKatrina Gwinn
National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS ONE 2:e1254. 2007..This resource should facilitate genetic discoveries which we anticipate will ultimately provide a better understanding of the biological mechanisms of neurodegeneration in ALS...- Olfactory ensheathing glia injections in Beijing: misleading patients with ALSSheena Chew
Department of Neurology, Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
Amyotroph Lateral Scler 8:314-6. 2007..Clinics that give experimental and potentially harmful treatments outside the construct of well-designed clinical trials put patients at risk and do a disservice to the ALS community... - Current clinical trials in amyotrophic lateral sclerosisJaydeep M Bhatt
Columbia University, Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Neurological Institute, New York, NY 10032, USA
Expert Opin Investig Drugs 16:1197-207. 2007..There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design... - Extensor digitorum brevis test and resistance to botulinum toxin type APaul H Gordon
Department of Neurology, ACC 2, University of New Mexico, 915 Camino de Salud NE, Albuquerque, New Mexico 87131, USA
Muscle Nerve 26:828-31. 2002..Four of five resistant patients had values outside the normal range. The EDB test is a simple quantitative method of detecting resistance to BTX-A, with a sensitivity of 80% and specificity of 94%...
Research Grants
- Phase III Trial of Minocycline in ALS:I-Clinical CenterPaul Gordon; Fiscal Year: 2006..P.I. Dr. Robert Miller). ..
- Phase III Trial of Minocycline in ALS:I-Clinical CenterPaul Gordon; Fiscal Year: 2007..P.I. Dr. Robert Miller). ..